Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CORTNASDAQ:INVANASDAQ:PCRXNASDAQ:SUPN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCORTCorcept Therapeutics$71.38+0.2%$71.56$29.42▼$117.33$7.57B0.191.14 million shs1.74 million shsINVAInnoviva$21.00-2.1%$19.40$15.95▼$22.00$1.32B0.37675,409 shs1.22 million shsPCRXPacira BioSciences$24.23+0.3%$25.47$11.16▼$29.61$1.12B0.52963,755 shs668,087 shsSUPNSupernus Pharmaceuticals$32.28-2.1%$32.14$25.55▼$40.28$1.81B0.71474,594 shs909,294 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCORTCorcept Therapeutics0.00%+1.88%-6.19%+21.68%+153.57%INVAInnoviva0.00%-3.18%+11.58%+21.60%+29.47%PCRXPacira BioSciences0.00%-0.04%-7.06%+0.37%-14.05%SUPNSupernus Pharmaceuticals0.00%+0.78%+0.75%+0.40%+21.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCORTCorcept Therapeutics4.6161 of 5 stars3.51.00.04.22.94.21.9INVAInnoviva4.2393 of 5 stars3.50.00.04.23.51.71.9PCRXPacira BioSciences2.4478 of 5 stars1.21.00.03.92.72.50.6SUPNSupernus Pharmaceuticals2.0539 of 5 stars2.21.00.04.11.80.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCORTCorcept Therapeutics 3.00Buy$138.2593.68% UpsideINVAInnoviva 3.00Buy$55.00161.90% UpsidePCRXPacira BioSciences 2.33Hold$26.449.14% UpsideSUPNSupernus Pharmaceuticals 2.33Hold$36.0011.52% UpsideCurrent Analyst Ratings BreakdownLatest SUPN, PCRX, INVA, and CORT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025PCRXPacira BioSciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $30.005/6/2025CORTCorcept TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$135.005/6/2025CORTCorcept TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$150.00 ➝ $145.004/8/2025PCRXPacira BioSciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/8/2025PCRXPacira BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$48.00 ➝ $65.004/3/2025CORTCorcept TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$128.00 ➝ $131.004/1/2025CORTCorcept TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$130.00 ➝ $142.003/31/2025CORTCorcept TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$76.00 ➝ $150.003/31/2025CORTCorcept TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$115.00 ➝ $150.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCORTCorcept Therapeutics$675.04M11.21$1.24 per share57.47$6.49 per share11.00INVAInnoviva$358.71M3.68$3.43 per share6.13$11.03 per share1.90PCRXPacira BioSciences$700.97M1.60$4.32 per share5.61$16.86 per share1.44SUPNSupernus Pharmaceuticals$661.82M2.73$4.17 per share7.74$18.76 per share1.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCORTCorcept Therapeutics$141.21M$1.1661.5338.58N/A19.33%20.40%16.64%8/4/2025 (Estimated)INVAInnoviva$23.39M-$1.01N/A13.55N/A-16.15%15.77%8.41%7/29/2025 (Estimated)PCRXPacira BioSciences-$99.56M-$2.28N/A9.43N/A-14.78%13.78%7.00%7/29/2025 (Estimated)SUPNSupernus Pharmaceuticals$73.86M$1.1129.0822.42N/A9.27%12.23%9.17%8/5/2025 (Estimated)Latest SUPN, PCRX, INVA, and CORT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025INVAInnovivaN/A$0.25N/A-$0.74N/A$88.63 million5/5/2025Q1 2025CORTCorcept Therapeutics$0.17$0.17N/A$0.17$177.93 million$157.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCORTCorcept TherapeuticsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ASUPNSupernus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCORTCorcept TherapeuticsN/A3.072.96INVAInnoviva0.402.482.30PCRXPacira BioSciences0.482.411.99SUPNSupernus PharmaceuticalsN/A2.442.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCORTCorcept Therapeutics93.61%INVAInnoviva99.12%PCRXPacira BioSciences99.73%SUPNSupernus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCORTCorcept Therapeutics20.80%INVAInnoviva2.25%PCRXPacira BioSciences6.40%SUPNSupernus Pharmaceuticals8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCORTCorcept Therapeutics300106.04 million83.99 millionOptionableINVAInnoviva10062.78 million61.36 millionOptionablePCRXPacira BioSciences72046.29 million43.33 millionOptionableSUPNSupernus Pharmaceuticals58055.99 million51.06 millionOptionableSUPN, PCRX, INVA, and CORT HeadlinesRecent News About These CompaniesSupernus Pharmaceuticals (NASDAQ:SUPN) Lowered to Hold Rating by Wall Street ZenJune 21 at 2:54 AM | marketbeat.comSAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGEJune 18, 2025 | businesswire.comSupernus Pharma to Buy Sage Therapeutics for Up to $795 MillionJune 17, 2025 | marketwatch.comSupernus enters depression drug market with up to $795 million Sage dealJune 17, 2025 | msn.comSupernus to acquire depression drugmaker SageJune 17, 2025 | msn.comSupernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage TherapeuticsJune 17, 2025 | msn.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.June 16, 2025 | prnewswire.comSupernus Pharmaceuticals (SUPN) to Acquire Sage Therapeutics in $795M DealJune 16, 2025 | gurufocus.comSupernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry ...June 16, 2025 | gurufocus.comSupernus Pharmaceuticals to Acquire Sage Therapeutics in a Strategic Move | SUPN stock newsJune 16, 2025 | gurufocus.comSage Therapeutics Stock Soars 35% After Sale to Supernus Pharmaceuticals. What We Know.June 16, 2025 | barrons.comSupernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry ...June 16, 2025 | gurufocus.comSupernus Pharma to acquire Sage Therapeutics in up to $795 million dealJune 16, 2025 | reuters.comSupernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product PortfolioJune 16, 2025 | globenewswire.comAzzad Asset Management Inc. ADV Acquires New Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)June 16, 2025 | marketbeat.comGAMMA Investing LLC Grows Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)June 16, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) and Nabriva Therapeutics (NASDAQ:NBRV) Financial SurveyJune 14, 2025 | americanbankingnews.comWedge Capital Management L L P NC Acquires 13,955 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)June 10, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Two Sigma Investments LPJune 7, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Acquires 11,304 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)June 5, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.62 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)June 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSUPN, PCRX, INVA, and CORT Company DescriptionsCorcept Therapeutics NASDAQ:CORT$71.38 +0.14 (+0.20%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$71.16 -0.22 (-0.31%) As of 06/20/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Innoviva NASDAQ:INVA$21.00 -0.46 (-2.14%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$20.99 -0.01 (-0.05%) As of 06/20/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Pacira BioSciences NASDAQ:PCRX$24.23 +0.08 (+0.33%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$24.23 0.00 (0.00%) As of 06/20/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.Supernus Pharmaceuticals NASDAQ:SUPN$32.28 -0.68 (-2.06%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$32.30 +0.02 (+0.08%) As of 06/20/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
